GlassScriptPhysician profile
Chad J Mcneil
NPI 1134326101
$63,802.10
in general payments reported to CMS, 2019-2025
19 companies · $3,455 in 2025
The $3,455 reported for 2025 was more than what 96% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,404 · 2020: $6,450 · 2021: $13K · 2022: $14K · 2023: $12K · 2024: $9,884 · 2025: $3,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $2,892 · Travel and Lodging: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,660.00 |
| Food and Beverage | $2,891.81 |
| Travel and Lodging | $205.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $32,013.59 | 2021-2025 | |
| Allergan, INC. | $25,762.13 | 2019-2022 | |
| Abbott Laboratories | $2,899.67 | 2019-2024 | Eterna, Proclaim, Octrode |
| Boston Scientific Corporation | $2,345.51 | 2022-2025 | Wavewriter Alpha Prime 16, General - Therapies, General - Pain Management |
| Nalu Medical, INC. | $118.41 | 2024-2025 | Nalu Neurostimulation System |
| Nevro Corp. | $113.24 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $83.43 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $76.42 | 2022 | |
| Amneal Pharmaceuticals LLC | $68.86 | 2023 | Lyvispah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.34 | 2025 | Relistor |
| Bioventus LLC | $56.36 | 2023-2024 | Durolane, Durolane |
| Pfizer INC. | $53.90 | 2020-2021 | |
| Amgen INC. | $36.32 | 2020-2022 | |
| Piramal Critical Care | $32.16 | 2019 | |
| Horizon Therapeutics Plc | $23.01 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $19.73 | 2023 | Intracept |
| Ferring Pharmaceuticals INC. | $15.38 | 2019 | |
| Medtronic USA, INC. | $11.32 | 2019 | |
| Stimwave Technologies Incorporated | $11.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Mcneil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.